Girardi, P.; Harutyunyan, S.; Neuhauser, I.; Glaninger, K.; Korda, O.; Nagy, G.; Nagy, E.; Szijártó, V.; Pall, D.; Szarka, K.;
et al. Evaluation of the Safety, Tolerability and Immunogenicity of ShigETEC, an Oral Live Attenuated Shigella-ETEC Vaccine in Placebo-Controlled Randomized Phase 1 Trial. Vaccines 2022, 10, 340.
https://doi.org/10.3390/vaccines10020340
AMA Style
Girardi P, Harutyunyan S, Neuhauser I, Glaninger K, Korda O, Nagy G, Nagy E, Szijártó V, Pall D, Szarka K,
et al. Evaluation of the Safety, Tolerability and Immunogenicity of ShigETEC, an Oral Live Attenuated Shigella-ETEC Vaccine in Placebo-Controlled Randomized Phase 1 Trial. Vaccines. 2022; 10(2):340.
https://doi.org/10.3390/vaccines10020340
Chicago/Turabian Style
Girardi, Petra, Shushan Harutyunyan, Irene Neuhauser, Katharina Glaninger, Orsolya Korda, Gábor Nagy, Eszter Nagy, Valéria Szijártó, Denes Pall, Krisztina Szarka,
and et al. 2022. "Evaluation of the Safety, Tolerability and Immunogenicity of ShigETEC, an Oral Live Attenuated Shigella-ETEC Vaccine in Placebo-Controlled Randomized Phase 1 Trial" Vaccines 10, no. 2: 340.
https://doi.org/10.3390/vaccines10020340
APA Style
Girardi, P., Harutyunyan, S., Neuhauser, I., Glaninger, K., Korda, O., Nagy, G., Nagy, E., Szijártó, V., Pall, D., Szarka, K., Kardos, G., Henics, T., & Malinoski, F. J.
(2022). Evaluation of the Safety, Tolerability and Immunogenicity of ShigETEC, an Oral Live Attenuated Shigella-ETEC Vaccine in Placebo-Controlled Randomized Phase 1 Trial. Vaccines, 10(2), 340.
https://doi.org/10.3390/vaccines10020340
